Followers | 439 |
Posts | 41282 |
Boards Moderated | 0 |
Alias Born | 10/07/2010 |
Thursday, October 13, 2016 1:43:13 PM
http://www.otcmarkets.com/financialReportViewer?symbol=MNZO&id=160529
Item 3: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers The Issuer has accepted Mr. Manzo's resignation as an officer and director of the Issuer. The 4,000,000 shares of Manzo Pharmaceuticals, Inc. Series A Preferred Stock have been conveyed to Gerasimos Alexander Antonios Morfesis.
Mr. Morfesis' address is 385 Whitcomb Boulevard, Tarpon Springs, Florida 34689. Mr. Morfesis is a real estate investor.
Arthur Smitherman, who had been the only remaining director of the Issuer, has been 3
removed and Mr. Morfesis is now the sole director of the Issuer.
Mr. Morfesis is a real estate investor with previous holdings in Chicago and the Tampa Bay area of Florida.
Mr. Morfesis was Involved in the “Black Metropolis” redevelopment plan in Chicago, and worked on the local board of a Habitat for Humanity Chapter in Chicago. Mr. Morfesis helped restructure Congress Theater in Chicago into a live venue success.
Mr. Morfesis has worked for a number of years in legal support work, researching and developing esoteric and successful defenses against bank attempts to improperly convert homeowners equity in the judicial foreclosure process. He has experience in restructurings and renegotiations of debts.
Mr. Morfesis attended Fairleigh Dickinson University and City College of New York. He has previously held a Mortgage License in Florida and real estate licenses in New York and Illinois.
Mr. Morfesis has no disciplinary history whatsoever, and has never had a criminal conviction, entry of a judgment or decree by a court of any jurisdiction that limited his involvement with any type of business, securities, commodities, or banking activities. Furthermore they have never had a finding or judgment against them nor any order by self-regulatory organizations of any kind.
As of the date of this information statement the only individual or entity owning more than 10% of the company’s common or preferred securities is as follows:
Gerasimos Alexander Antonios Morfesis 385 Whitcomb Boulevard Tarpon Springs, Florida 34689
Ownership: 4,000,000 Shares of Preferred Series A Shares
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM